All In Biotech

Drug Trial Radar · NCT01259492

Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)

A 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate HCl Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD

Last checked: Nov 19, 2026Latest source record: Oct 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 725 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

725

Actual

Start

Nov 2010

Primary completion

Aug 2012

Study completion Aug 2012

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 14, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).

Conditions

  • Attention Deficit/Hyperactivity Disorder

Interventions

  • PlaceboDrug

    Placebo Comparator: Placebo

  • Ritalin LA 20 mgDrug

    Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.

  • Ritalin LA 30 mgDrug

    Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline of Period 1 (Baseline 1) to End of Period 1 on Attention-Deficit/Hyperactivity Disorder Rating Scale (DSM-IV ADHD RS) Total Score by TreatmentTime frame: Baseline 1 to End of Period 1 (Week 9)
  2. Change From Baseline Period 1 (Baseline 1) to End of Period 1 on Sheehan Disability Scale (SDS) Total Score by TreatmentTime frame: Baseline 1 to End of Period 1 (Week 9)
  3. Percentage of Participants With Treatment Failures During Period 3Time frame: Baseline Period 1 (Baseline 1) and Baseline Period 3 (Baseline 2) to End of Week 40

Locations

68 sites in 9 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Little Rock, Arkansas

  • Novartis Investigative Site

    Beverly Hills, California

  • Novartis Investigative Site

    Spring Valley, California

  • Novartis Investigative Site

    Bradenton, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Orlando, Florida

  • Novartis Investigative Site

    West Plam Beach, Florida

  • Novartis Investigative Site

    Libertyville, Illinois

  • Novartis Investigative Site

    Owensboro, Kentucky

  • Novartis Investigative Site

    Troy, Michigan

  • Novartis Investigative Site

    Las Vegas, Nevada

  • Novartis Investigative Site

    Las Vegas, Nevada

  • Novartis Investigative Site

    Willingboro, New Jersey

  • Novartis Investigative Site

    Fargo, North Dakota

  • Novartis Investigative Site

    Columbus, Ohio

  • Novartis Investigative Site

    Oklahoma City, Oklahoma

  • Novartis Investigative Site

    Philadelphia, Pennsylvania

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    Bellevue, Washington

  • Novartis Investigative Site

    Seattle, Washington

  • Novartis Investigative Site

    Kessel-Lo, Belgium

  • Novartis Investigative Site

    Mechelen, Belgium

  • Novartis Investigative Site

    Bruges, Belgium, Belgium

  • Novartis Investigative Site

    Heusden-Zolder, Belgium, Belgium

  • Novartis Investigative Site

    Kortenberg, Belgium, Belgium

  • Novartis Investigative Site

    Uccle, Belgium, Belgium

  • Novartis Investigative Site

    Antioquia, Colombia

  • Novartis Investigative Site

    Bogotá, Colombia

  • Novartis Investigative Site

    Santa Fe de Antioquia, Antioquia, Colombia

  • Novartis Investigative Site

    Århus C, Denmark

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Ellwangen, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Germany

  • Novartis Investigative Site

    Hagen, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Homburg, Germany

  • Novartis Investigative Site

    Landau, Germany

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.